Experience

Davis Polk advised BiondVax Pharmaceuticals Ltd. in connection with its registered at-the-market offering of shares of its American depositary shares for up to a maximum offering price of …

Davis Polk advised the initial purchasers in connection with the Rule 144A/Regulation S offering by Fresnillo plc of 4.250% senior notes due 2050 in the aggregate amount of $850…

Davis Polk advised Boqii Holding Limited on its SEC-registered initial public offering of 7,000,000 American depositary shares. Each ADS represents 0.75 Class A ordinary share of Boqii…

Davis Polk advised the underwriters in connection with an offering by Kemper Corporation of $400 million aggregate principal amount of its 2.400% senior notes due 2030. Kemper…

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of €6.25 billion aggregate principal amount of notes by Medtronic Global…

Davis Polk advised Kingsoft Cloud Holdings Limited and certain selling shareholders on its approximately $509 million SEC-registered follow-on public offering of 16,421,576 American…

 Davis Polk advised ADC Therapeutics SA on its SEC-registered offering of 6,000,000 common shares for total gross proceeds of $204 million. ADC Therapeutics is listed on the New York…

Davis Polk advised Zai Lab Limited in connection with its secondary listing and initial public offering on the Hong Kong Stock Exchange. Zai Lab is the first company listed under both…

Davis Polk advised NatWest Group plc in connection with its cash tender offer for any and all of certain series of its outstanding bank capital securities.NatWest Group is the holding…

Davis Polk advised the joint bookrunners and representatives of the several underwriters in connection with concurrent SEC-registered offerings by (1) B.A.T Capital Corporation of $1.75…